Funding cuts create perfect storm that could capsize cancer research in the UK 29 Mar 2021 The UK’s science budget faces catastrophic cuts – on top of the alarming impact of Covid-19 on medical research organisations. Professor Paul Workman, Chief Executive of the ICR, warns that without a change in course from the Government, cancer research in the UK is heading for a perfect storm with an impact that could last decades. Find out more Show/Hide
Trying to drug the apparently undruggable, and what it can teach us 04 Nov 2020 Professor Paul Workman reflects in depth on his experience in trying to drug a particularly challenging cancer target, and why it is always important to be clear about the risks and benefits of a drug discovery project – and to share the results with the research community. Find out more Show/Hide
Climbing the peaks of drug discovery – tackling the most challenging targets with ingenuity and realism 21 Oct 2020 Professor Paul Workman argues that creating drugs is a bit like climbing mountains – and as with scaling a craggy slope versus a smooth wall of rock, tackling some disease targets is easier than others. Find out more Show/Hide
Book published in tribute to the late Dr Susan Lindquist – HSF1 and Molecular Chaperones in Biology and Cancer 24 Apr 2020
Understanding the off-target effects of cancer drugs – and how they could lead us to new forms of treatment 03 Mar 2020
Our manifesto for cancer drug discovery and development – focusing on innovation to tackle treatment resistance and meeting patients’ needs 30 Apr 2019